Table 2.
Main studies and results for mepolizumab in asthma
| Year | Study | FEV1 increase | Acute exacerbations reduction | Blood eosinophils count reduction | Sputum eosinophils count reduction | Decrease in prednisone use | AQLQ | ACQ | Reduction in airway inflammation | Comments |
|---|---|---|---|---|---|---|---|---|---|---|
| 2003 | Flood-Page et al47 | NS | NA | S | NA | NA | NA | NA | S | |
| 2007 | Flood-Page et al35 | NA | NS | S | NA | NA | NA | NA | NA | Data not statistically significant due to incorrect selection of sample |
| 2009 | Haldar et al36 | NS | S | S | S | NA | S | NA | NS | 61 subjects with eosinophilic asthma and recurrent exacerbation |
| 2009 | Nair et al37 | S | S | S | S | S | NA | NA | NA | 20 subjects with persistent sputum eosinophilia and symptoms despite prednisone treatment |
| 2012 | Pavord et al38 | NS | S | S | S | NA | NS | NS | NA | 621 patients with recurrent severe asthma exacerbations and signs of eosinophilic inflammation |
| 2014 | Ortega et al51 | S | S | NA | NA | NA | NA | S | NA | 576 patients with recurrent asthma exacerbations and eosinophilic inflammations |
Abbreviations: NA, not applicable; NS, not significant; S, significant; FEV1, forced expiratory volume in 1 second; AQLQ; Asthma Quality of Life Questionnaire; ACQ, Asthma Control Questionnaire.